1	Pharmacokinetics of anti-tuberculosis drugs in multidrug resistant
2	tuberculosis patients in India
3	Llementh Kumer ΔK^{a^*} Netersian DI ^a Kennen T ^a Gridher D ^b Kumer C ^b Mined Kumer λ^{b} Comethi
4 5	Hemanth Kumar AK ^{a*} , Natarajan PL ^a , Kannan T ^a , Sridhar R ^b , Kumar S ^b , Vinod Kumar V ^b , Gomathi NS ^a , Bharathiraja T ^a , Sudha V ^a , Balaji S ^a , Rameshkumar S ^a , Dina Nair ^a , Tripathy SP ^{a,} Geetha R ^a
6	
7	^a National Institute for Research in Tuberculosis, Chennai
8	^b Government hospital of Thoracic Medicine, Chennai
9	
10	
11	Running head: PK of anti-TB drugs in MDR TB
12 13	
15	
14	
15	
16	*Correspondence:
17	Dr. A K Hemanth Kumar
18	Scientist 'D' & Head
19	Department of Clinical Pharmacology
20	National Institute for Research in Tuberculosis
21	Mayor Sathyamoorthy Road
22	Chetpet, Chennai – 600 031
23	India
24	Ph.no: 91-44-28369650
25	Email: hemanthkumarak@nirt.res.in
26	Fax: 91-44-28362528
27	
28	
29	NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
30	

31 Abstract

Programmatic Management of multidrug resistant tuberculosis (MDR TB) services were introduced in the Indian TB control programme in 2007. A pharmacokinetic (PK) study of drugs used to treat MDR TB, namely levofloxacin (LFX), ethionamide (ETH), cycloserine (CS), pyrazinamide (PZA), moxifloxacin (MFX) and isoniazid (INH) was undertaken in adult MDR TB patients treated according to the prevailing guidelines in India. Factors influencing drug PK and end-of-intensive phase (IP) status were also determined. We recruited 350 MDR TB patients receiving anti-TB treatment (ATT) in the Indian Government programme in south India. At steady state, serial blood samples were collected, after supervised drug administration. Status at end of IP was noted from the programme records. Of the 303 patients for whom end-of-IP status was known, 214 were culture negative (responders), while 45 patients were either culture positive or required change of regimen or had died before completion of IP (non-responders). The median C_{max} (2.0 vs 2.9µg/ml; p = 0.005) and AUC₀₋₁₂ (12.2 vs 17.0µg/ml.h; p = 0.002) of ETH were significantly lower in non-responders than responders at IP. In multivariate logistic regression analysis, after excluding defaulters and adjusting for confounders, AUC_{0-12} of ETH significantly influenced end-of-IP status (aOR - 1.065; 95% CI: 1.001 - 1.134; p = 0.047). Drug doses used currently in the programme produced optimal drug concentrations in majority of patients. ETH played a major role in the MDR TB combination regimen and was a key determinant of end-of-IP status.

Keywords: Multi-drug tuberculosis; Pharmacokinetics; anti-TB drugs; India

The burden of multidrug-resistant (MDR) tuberculosis (TB) is of major interest and concern at global, regional and country levels. In 2018, there were approximately half a million (range 417000 - 556000) new cases of rifampicin-resistant (RR) TB, of which 78% had MDR TB (1). India accounts for 27% of the total MDR TB cases worldwide, which is the highest for any country. This is followed by China (14%) and the Russian federation (9%).

The National TB Elimination Programme (NTEP) in India had introduced Programmatic 71 Management of MDR TB (PMDT) services in 2007, and a complete geographic coverage was 72 achieved in 2013 (2). Under this programme, MDR TB patients were treated with six drugs which 73 included an aminoglycoside and a fluoroquinolone for a total period of 24 months. The intensive 74 phase (IP) of treatment was for 6 months comprising of kanamycin (Km), levofloxacin (LFX), 75 ethionamide (ETH), cycloserine (CS), pyrazinamide (PZA) and ethambutol (EMB) daily, followed 76 by the continuation phase of treatment for the remaining 18 months with LFX, Eth, CS and EMB 77 daily. If the 4th month culture for *M. tuberculosis* was positive, the intensive phase was extended 78 up to 9 months. Subsequently, in 2018, the regimens were revised and the duration of treatment 79 was shorter for a period of 9 months. In the revised regimen, the initial IP was for 4 months, during 80 which patients received Km, moxifloxacin (MFX), high dose isoniazid (INH), PZA, clofazimine 81 (CFZ), Eth and EMB daily. This was followed by the continuation phase for the remaining 5 82 months, during which patients received MFX, CFZ, PZA and EMB daily. In both regimens, drug 83 doses were based on body weight and were available in four weight bands, namely, 16 - 29 kg, 30 84 - 45 kg, 46 - 70 kg and > 70 kg (Table 1). 85

Cure rates observed among MDR TB patients from different studies varied from 31% to 75%, the 86 treatment regimens being different in these studies. A study from south India on the management 87 of MDR TB, reported a cure rate of 38%, with failure (25%), default (24%) and death (12%) (3). 88 The reasons for development of MDR TB could be due to microbial, clinical or programmatic 89 issues. Clinical characteristics of patients have also been recognized wherein appropriately 90 administered drug doses may not achieve necessary drug levels to deal with all populations of 91 mycobacteria. Maintaining therapeutic drug concentrations in blood is an important requisite to 92 achieve satisfactory treatment outcome. The National Jewish Medical and Research Centre at 93 Denver, CO, USA recommends measurement of serum concentrations of second-line anti-TB 94 drugs early in the course of treatment, so that poor drug absorption can be dealt with, in a timely 95 manner by optimizing drug doses (4). 96

A few studies have reported on the pharmacokinetics (PK) of second-line anti-TB drugs. A population PK study in 14 MDR TB patients from Korea has been reported (5). Another study from Tanzania has examined plasma activity of certain second-line anti-TB drugs in 25 patients with MDR TB (6). Park and others from the Republic of Korea have described the PK of second-line anti-TB medications in healthy volunteers (7). However, there is a paucity of PK data of second-

line anti-TB drugs in MDR TB patients from India. We undertook a prospective study to determine the PK of certain anti-TB drugs (LFX, MFX, Eth, CS, PZA, INH) in adult MDR TB patients in south India treated according to the prevailing NTEP guidelines. We also examined factors that influenced drug PK and culture status at end of IP.

106 Methods

107 Patients

A prospective study was undertaken in adult patients with MDR TB receiving anti-TB treatment (ATT) at the Government Hospital for Thoracic Medicine, Chennai, India during June 2016 to September 2019. All the patients were bacteriologically confirmed to have MDR TB based on drug susceptibility tests. Diagnosis and treatment were in accordance with the NTEP guidelines (2 - 3 of protocol). All the patients received drugs from the NTEP under direct supervision.

Patients meeting the following study criteria were recruited: (i) aged 18 years or above (ii) body weight > 30kg (iii) minimum seven doses of ATT drugs (iv) not very sick or moribund and (v) willing to participate and give informed written consent. A structured questionnaire was used to collect patient details. The study was approved by the Institutional Ethics Committee.

117 Study procedures

The PK study was conducted at the Government Hospital of Thoracic Medicine, Chennai, India 118 after patients have had at least two weeks of treatment. Eligible patients were requested to get 119 admitted to the hospital ward at least a day prior to start of the study. On the day of the study, a 120 sample of blood (2 ml) was collected (pre-dosing). The prescribed anti-TB drugs were 121 administered to the patients under supervision. Thereafter, serial blood samples were collected at 122 1. 2. 4. 6. 8 and 12 hours after drug administration. Those with a known history of type 2 diabetes 123 mellitus (DM), with or without random blood glucose > 200mg/dl on the study day was considered 124 diabetic. The patients' body mass index (BMI) was calculated from their height and body weight. A 125 BMI below 18.5 was considered malnourished. 126

127 **Drug estimations**

Plasma concentrations of LFX, MFX, ETH, CS, INH and PZA were estimated by High Performance Liquid Chromatography (HPLC) (Shimadzu Corporation, Kyoto, Japan) according to validated methods described elsewhere. In brief, the method to estimate LFX and MFX involved deproteinisation of the sample with perchloric acid and analysis of the supernatant using a reversed-phase C18 column (150mm) using fluorescence detector set at an excitation wavelength of 290 nm and an emission wavelength of 460 nm. The mobile phase consisted of a mixture of phosphate buffer and acetonitrile. The retention times of LFX and MFX were 1.8 and 4.6 minutes respectively (8, 9).

Plasma INH and PZA were estimated simultaneously by extraction using parahydrobenzaldehyde and trifluoro acetic acid. Analysis was performed using a C_8 column at 267nm. The mobile phase consisted of water: methanol containing perchloric acid and tetrabutyl n-ammonium hydroxide. The retention times of PZA and INH were 3 and 5.5 minutes respectively (10).

The method for estimation of CS involved extraction of the drug using solid phase extraction cartridges. The analytical column was Atlantis T3 and the mobile phase was a mixture of phosphate buffer, acetonitrile and isopropyl alcohol. The retention time of CS was 4.8 minutes (11).

The method for estimation of ETH involved deproteinisation of the sample with perchloric acid and analysis of the supernatant using a reversed-phase CN column (150mm) and UV detector set at 267 nm. The mobile phase consisted of Milli-Q water and methanol containing 0.05% perchloric acid and 0.1% tetrabutyl N-ammonium hydroxide. The retention time of ETH was 4.9 minutes (12).

Calculation of Pharmacokinetic variables: Based on plasma concentration of drugs at different time-points, certain PK variables such as peak concentration (C_{max}), time at which C_{max} was attained (T_{max}), area under the concentration-time curve (AUC₀₋₁₂) and half-life ($t_{1/2}$) were calculated based on non-compartmental analysis using STATA 15.0 (StataCorp, College Station, Texas, USA).

153 Follow-up during treatment

All patients continued to receive ATT according to NTEP guidelines. Culture results at end of intensive phase, wherever available were recorded from the treatment card of patients. Based on the culture status at end of IP, patients were divided into two groups - (i) those who were culture negative (responders) and (ii) those who remained culture positive, those who had died during IP, and those who required change in regimen (non-responders).

Statistical Evaluation: Data were analysed using STATA 15.0 (StataCorp, College Station, 159 Texas, USA). Shapiro-Wilks test was used to assess normality of the PK data. Values were 160 expressed as median and range. Non-parametric Mann-Whitney U test was used to compare 161 subgroups. Proportion of patients having C_{max} within the therapeutic ranges (8 - 13µg/ml for LFX; 162 20 - 60µg/ml for PZA; 2 - 5µg/ml for ETH; 20 - 35µg/ml for CS; 3 - 6µg/ml for INH 300/600mg; 9 -163 15µg/ml for INH 900mg) (13) were calculated. Drug C_{max} and AUC₀₋₁₂ were compared between 164 responders and non-responders to ATT. Multiple linear regression analysis by stepwise method 165 was carried out to identify factors that influenced C_{max} and AUC₀₋₈ of drugs. Logistic regression 166 model was used to identity the association of C_{max} and AUC₀₋₁₂ with culture negativity at the end of 167 IP. Some of the following factors such as age, gender, body weight, smoking status, alcoholism, 168 DM, culture and drug doses were considered in the regression model after considering the 169 variance inflation factor (VIF) and co-linearity. A p < 0.05 was considered statistically significant. 170

171

172

173 Sample Size

The sample size was calculated based on the study of Mpagama et al (6), who reported the peak concentration of ETH to be 3.6µg/ml with the standard deviation of 1.8. Assuming a marginal error of 20% and 10% refusal for blood draw, the sample size required was 346 patients.

177 Results

There were two groups of patients; those who were initially recruited received the LFX containing 178 regimen (Regimen 1) and subsequently when the programme revised the regimen, the patients 179 were being treated with the MFX-containing regimen (Regimen 2). A total of 350 patients took part 180 in the study, among whom 274 and 76 patients respectively received regimens 1 and 2. We 181 analysed combined data from both regimens and also performed regimen-wise analysis. We 182 present results obtained from the combined data. Details of all the patients recruited to the study 183 are shown in Table 2. Overall, patients with DM constituted 42% of the study population. About 184 62.3% of the patients had BMI <18.5kg/sq.m. A high proportion of patients were males (82.3%), 185 had pulmonary TB (97.1%) and were previously treatment with Category II ATT regimen (70.3%). 186

The PK parameters of LFX, ETH, CS, PZA, MFX, and INH are shown in Table 3. PK data was 187 available for 252, 259, 235, 300, 69, 63 patients for LFX, ETH, CS, PZA, MFX and INH 188 respectively. Missing values were mainly because patient had not taken a particular drug on the 189 study day or blood sample was not sufficient to undertake drug estimation. The median T_{max} was 2 190 hours for all the drugs tested in this study. The number of patients with C_{max} of LFX within the 191 therapeutic range (8 - 13µg/ml) was 126 (50%). The corresponding numbers for ETH (2 - 5µg/ml), 192 CS (20 - 35µg/ml), PZA (20 - 60µg/ml), MFX (3 - 5µg/ml), INH 300mg/600mg (3 - 6µg/ml), INH 193 900mg (9 - 15µg/ml) were 171 (66%), 83 (35.3%), 211 (70.3%), 22 (31.9%), 3 (7.5%) and 11 194 (47.8%) respectively. A high proportion of patients had C_{max} of CS (57.9%), MFX (58%) and INH 195 300mg/600mg (85%) above the upper limit of the therapeutic range. Those with sub-therapeutic 196 C_{max} ranged from 3.3% for PZA to 27.4% for ETH. 197

Drug C_{max} and AUC_{0-12} of the different groups of patients are shown in Tables 4 and 5 respectively. Patients above 45 years of age had significantly higher C_{max} and AUC_{0-12} of LFX than those below 45 years (C_{max} : 12.0 vs 11.2µg/ml, p = 0.041; AUC_{0-12} : 94.7 vs 82.0µg/ml.h, p = 0.004). The AUC_{0-12} of CS was significantly higher in male than female patients (354.8 vs 307.7, p = 0.004). The C_{max} and AUC_{0-12} of LFX and CS were significantly higher in patients with BMI ≥ 18.5 than those with BMI < 18.5. Patients with DM had significantly higher C_{max} of LFX (12.0 vs 11.1µg/ml; p = 0.014) and CS (42.4 vs 35.5µg/ml; p = 0.004) than those without DM. The AUC_{0-12} of CS was also

significantly higher in those with DM than those without DM (388.7 vs 323.9µg/ml.h; p = 0.004). Patients who consumed alcohol had higher C_{max} and AUC_{0-12} of CS, the difference attaining statistical significance for AUC_{0-12} only (383.9 vs 323.4µg/ml.h; p = 0.017). Non-responding patients had significantly lower C_{max} (2.5 vs 2.9µg/ml; p = 0.040) and AUC_{0-12} (14.4 vs 16.8µg/ml.h; p = 0.034) of ETH than responders at end of IP.

In multiple linear regression model, we determined factors that had an impact on C_{max} and AUC_{0-12} of drugs. Using C_{max} as a dependent variable patients with BMI > 18.5kg/m² were likely to have 1.4 and 0.3µg/ml respectively of LFX and ETH C_{max} higher than those with BMI <18.5kg/m². Patients with culture positive *M. tuberculosis* were likely have 0.4µg/ml ETH C_{max} lower than those with culture negative *M. tuberculosis*. An increase of one unit of drug dose taken was likely to cause increases in the C_{max} of PZA, MFX and INH by 0.5µg/ml, 0.3µg/ml and 0.7µg/ml respectively.

Using AUC₀₋₁₂ as the dependent variable and adjusting for co-variates, age (LFX and ETH), gender (CS), BMI (LFX, ETH and CS), alcoholism (ETH), culture status (ETH), and mg/kg drug dose (ETH, PZA and MFX) were significant.

Of the 350 patients recruited to the study, status at end of IP were available for 303 patients in the NTEP records. Among them, 214 were responders, while 45 patients were non-responders at end of IP. Patients who had defaulted treatment (n = 44) were excluded from analysis. The median C_{max} (2.0 vs 2.9µg/ml; p = 0.005) and AUC₀₋₁₂ (12.2 vs 17.0µg/ml.h; p = 0.002) of ETH were significantly lower in non-responders compared to responders (Figures 1A and B).

The influence of factors such as age, gender, body weight, smoking, alcohol use, DM and C_{max}/AUC_{0-12} of LFX, ETH, CS, PZA, MFX and INH on end of IP status were tested. After excluding defaulters and adjusting for confounders, AUC_{0-12} of ETH was observed to significantly influence end of IP status (aOR - 1.065; 95% CI: 1.001 - 1.134; p = 0.047). The chance of having culture negativity at end of IP was higher by having AUC_{0-12} of ETH increased by 7% (Table 6).

229 Discussion

Effective control of MDR TB remains a challenge since second-line anti-TB medications are less potent, may require longer treatment duration, have a narrow therapeutic range and have greater number of side effects than first-line drugs (14). Hence treatment outcomes for MDR TB remain sub-optimal compared to drug-susceptible TB. Furthermore, PK tools such as plasma drug concentrations and MIC testing are not readily available in most TB endemic settings and it remains unclear how such measurements are best utilised.

The importance of optimised drug exposure, leading to greater bacterial killing and better outcomes has been shown in both murine models and human experience (15 - 17). In this prospective cohort study, we have described the PK of anti-TB drugs used in the treatment of MDR TB in India, and factors that were likely to influence status at end of IP. A higher proportion

of patients had C_{max} of LFX, ETH, PZA and INH 900mg within the therapeutic range. While this is 240 quite encouraging, we did observe a higher proportion of patients having C_{max} of CS, MFX, and 241 INH 300/600mg above the therapeutic range. The reason for higher proportion of patients who 242 received a relatively lower INH dose having C_{max} above the therapeutic range than those who 243 received a higher dose remains unclear, although patients' INH acetylator status would have 244 thrown some light on this issue. However, INH acetylator status was not determined in this study. 245 Our finding of 58% of patients having C_{max} of CS above the therapeutic range is in agreement with 246 that reported by Mpagama et al, which was 52% in their study (6). Using hollow fiber system 247 model of TB, Deshpande et al, determined the susceptibility breakpoint of CS, and reported that 248 drug doses required to achieve bacterial killing in patients was high, which was likely to cause 249 toxicity (18). In this study, we did not observe major adverse events due to CS at the time of the 250 PK sampling day. It should be pointed out that majority of the patients had their PK study 251 conducted within 4 weeks of treatment initiation. Psychosis as a side effect due to CS generally 252 shows up after a month of treatment: however, follow-up of patients beyond the PK study was not 253 part of this study. . 254

Our observation that a small proportion of patients only had sub-therapeutic C_{max} points to the fact 255 that drug doses used in the NTEP were guite adequate. A population PK study by Chigutsa and 256 others in South African MDR TB patients reported a high proportion of patients failed to achieve 257 the target of loxacin exposure and suggested that LFX or MFX would be ideal fluoroquinolones to 258 treat MDR TB (19). According to the PMDT guidelines in India, LFX was part of the multi-drug 259 regimen and the revised shorter regimen had MFX in the place of LFX. Our observation of half of 260 261 the patients having optimal C_{max} of LFX contradicts the findings of Mpagama et al, who reported LFX concentrations were frequently lower in MDR TB patients in Tanzania (6). Using nonlinear 262 mixed-effects modelling, a population PK study of PZA suggested 1500mg, 1750mg and 2000mg 263 PZA doses for MDR TB patients having weight bands upto 50kg, 51-70kg and above 70kg 264 respectively (20). The PZA doses followed in the NTEP are almost similar to that recommended in 265 the South African study. 266

A direct comparison of PK data of the drugs examined in this study could be compared with that reported by others, since the Korean study was performed in healthy volunteers (7) and the Tanzanian study examined drug concentrations only at 2 hours post-dosing (6). Furthermore, these studies were conducted in small numbers, 14 healthy volunteers and 25 patients.

Patients above 45 years of age seemed to have higher C_{max} and AUC_{0-12} of LFX, probably due to slower metabolism of the drug with aging. Female patients were observed to have higher exposure of CS than their male counterparts. Although not many studies have reported gender based differences in second-line anti-TB medications, a similar trend has been observed with respect to first-line anti-TB drugs (21 - 23). Our finding of patients with higher BMI having higher

C_{max} and AUC₀₋₁₂ of LFX and CS are not consistent with that reported with respect to first-line 276 drugs (20). Multivariate regression analysis also seemed to show BMI having a direct relationship 277 with drug concentrations. Likewise, higher LFX and CS concentrations observed in those with DM 278 than those without DM is also not in line with certain reports on RMP, INH and PZA (21, 24, 25). 279 While INH and PZA concentrations were lower in drug susceptible TB patients with DM than those 280 without DM (25, 26), no differences were observed in the case of MDR TB patients with and 281 without DM. It could be hypothesised that the metabolic pathways of drugs are different in patients 282 with drug susceptible and drug resistant TB, although the possibility of drug-drug interactions 283 cannot be ruled out. Nonetheless, this observation requires some attention and confirmation in 284 other studies. 285

The study showed that non-responding patients to ATT having lower C_{max} and AUC₀₋₁₂ of ETH than 286 responders is quite significant. We combined three different groups of patients as non-responders, 287 which included those who required a change of regimen. According to the NTEP, MDR TB 288 patients showing signs of clinical deterioration and becoming morbid have their treatment changed 289 to a bedaguiline - containing regimen. Thus, culture positives at end of IP, clinical failures and 290 deaths before completion of IP were combined and considered as non-responders. The PMDT 291 guidelines in India, recommends ETH as part of the MDR TB treatment regimen both initially and 292 in the revised regimen. Using a multidose hollow fiber system model, Deshpande et al, 293 demonstrated that ETH had a reasonable kill rate and that it was an important contributor to MDR 294 TB treatment regimens (27). Furthermore, suboptimal ETH exposure was likely to cause efflux 295 pump - mediated acquired drug resistance. Our study findings of C_{max} and AUC₀₋₁₂ of ETH being 296 higher in those who had culture conversion at end of IP than those who did not, and ETH 297 exposure emerging as a significant factor impacting end-of-IP status (after adjusting for 298 confounding factors and excluding defaulters) are consistent with the study of Deshpande and 299 300 others (27). In the light of these findings, it is crucial to include ETH as a part of the MDR TB treatment regimen, and ensure that therapeutic concentrations of ETH are maintained. 301

In multivariate regression analysis, we demonstrated drug doses to have a significant influence on the plasma concentrations of ETH, PZA, MFX and INH, and there was a direct relationship. Increasing drug doses was likely to boost drug concentrations, although one needs to be cautious about occurrence of toxic effects.

Our study findings are based on data analysed from all the 350 patients. We also performed regimen-wise analysis. Of the drugs examined in this study, ETH and PZA were present in both the regimens. No striking differences were observed in the PK profile of drugs in either regimen. This observation was made with respect to patients maintaining therapeutic concentrations, groupwise comparisons and factors influencing drug PK. It should however be added that the study was not designed to examine drug-drug interactions, about which not much is known.

The strength of the study was the large sample size and understanding the association between drug concentrations and patients' status at end of IP. The study was however, limited by the fact that we did not follow up patients till end of treatment. Hence treatment outcomes and occurrence of adverse reactions to drugs were not known. However, assessing end-of-treatment outcome in MDR TB studies is quite cumbersome due to the long duration of treatment. Determination of INH acetylator status could have provided additional information.

In summary, this is the first report describing the PK of second-line anti-TB drugs in MDR TB 318 patients in India. All patients were being treated according to the NTEP guidelines under direct 319 supervision, ensuring treatment regularity. The study conducted in a fairly large, adequately 320 powered sample size has demonstrated that the drug doses used currently in the programme 321 produced optimal drug concentrations in majority of patients. ETH played a major role in the MDR 322 TB combination regimen and was a key determinant of end-of-IP status. Future studies should 323 adopt a comprehensive approach assessing drug exposure, individual minimum inhibitory 324 concentrations and outcome. Researchers from China are aiming to conduct a translational study 325 that would characterise second-line anti-TB drug exposures and relate them to individual MICs 326 (28). It is important to carry out similar PK/PD studies in different parts of India, in order to 327 generalise the findings. 328

329 Acknowledgements

The authors thank the patients who took part in the study, A Vijayakumar for drug estimations by HPLC, clinic nurses of NIRT for blood collections, and secretarial assistance by S. Sasikumar.

332

333 Authors' contributions

AKH and GR designed the study, AKH wrote the study protocol and obtained regulatory approvals, RS, PLN, SRK, DN and SK supervised patient recruitment, PLN and TB conducted the study, AKH supervised drug estimations, VS and TB performed drug estimations, NSG and AB supervised bacteriological investigations, TK performed statistical analysis and GR drafted the manuscript.

339

340 Potential conflict of interest: None

- 341
- 342
- 343
- 344
- 345

- 346
- 347
- 348
- 349
- 350

351 **References**

- 1. Global TB report, 2019. Available at: http://www.who.int/tb/publications/global_report/en/
- 2. RNTCP Guidelines for Programmatic Management of Drug Resistant Tuberculosis
 (PMDT) in India, 2012. Available at: <u>https://tbcindia.gov.in</u>
- Thomas A, Ramachandran R, Rehman F, Jaggarajamma K, Santha T, Selvakumar N,
 Krishnan N, Nalini SM, Sundaram V, Fraser W, Narayanan PR. Management of multi-drug
 resistant tuberculosis in the field Tuberculosis Research Centre experience. Indian J Tub
 2007; 54: 117-124
- Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 2002; 62:
 2169–2183
- 5. Chang MJ, Jin B, Chae J, Yun H, Kim ES, Lee YJ, Cho YJ, Yoon HI, Lee CT, Park KU,
 Song J, Lee JH, Park JS. Population pharmacokinetics of moxifloxacin, cycloserine, p aminosalicylic acid and kanamycin for the treatment of multi-drug-resistant tuberculosis. Int
 J Antimicrob Agents 2017; 49 : 677-687. doi: 10.1016/j.ijantimicag.2017.01.024
- Mpagama SG, Ndusilo N, Stroup S, Kumburu H, Peloquin CA, Gratz J, Houpt ER, Kibiki
 GS, Heyself SK. Plasma drug acitivity in patients on treatment for multi-drug resistant
 tuberculosis. Antimicrob Agents Chemother. 2014;58:782-788. doi: 10.1128/AAC.01549-13
- Park S, Oh J, Jang K, Yoon J, Moon SJ, Park SJ, Lee JH, Song J, Jang IJ, Yu KS, Chung
 JY. Pharmacokinetics of second-line antituberculosis drugs after multiple administrations in
 healthy volunteers. Antimicrob Agents Chemother 2015; 59: 4429 4435. doi:
 10.1128/AAC.00354-15
- Hemanth Kumar AK, Sudha V, Ramachandran G. A Simple and Rapid Liquid
 Chromatography method for determination of Levofloxacin in Plasma. SAARC J TB, Lung
 Diseases & HIV/AIDS, 2016; XIII: 28 33
- Hemanth Kumar AK, Geetha Ramachandran. Simple and rapid liquid chromatography method for determination of moxifloxacin in plasma. J Chromatogr B Analyt Technol Biomed Life Sci, 2009; 877: 1205-1208. doi: 10.1016/j.jchromb.2009.02.042
- 37810. Hemanth Kumar AK, Sudha V, Geetha Ramachandran. Simple and rapid liquid379chromatography method for simultaneous determination of isoniazid and pyrazinamide in

- plasma. SAARC J TB, Lung diseases & HIV/AIDS 2012; 9: 13 18.
 DOI: https://doi.org/10.3126/saarctb.v9i1.6960
- 11. Hemanth Kumar AK, Polisetty AK, Sudha V, Vijayakumar A, Geetha Ramachandran. A
 Selective and sensitive high performance liquid chromatography assay for the
 determination of cycloserine in human plasma. Ind J Tub 2018; 65: 118 123.
 doi: 10.1128/AAC.02410-17
- 12. Hemanth Kumar AK, Sudha V, Geetha Ramachandran. Simple and rapid high pressure
 liquid chromatography methods for estimation of ethionamide in plasma. Asian J Biomed
 Pharmaceut Sci 2014; 04: 1 5
- 13. Abdullah A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: an
 update. Drugs 2014; 74: 839-854. doi: 10.1007/s40265-014-0222-8
- 14. Shenoi S, Heysell SK, Moll A, Friedland G. Multidrug-resistant and extensively drug resistant tuberculosis: consequences for the global HIV community. Curr Opin Infect
 Dis 2009; 22:11–17. 10.1097/QCO.0b013e3283210020. doi:
 10.1097/QCO.0b013e3283210020
- 15. Zhang M, Li SY, Rosenthal IM, Almeida DV, Ahmad Z, Converse PJ, Peloquin CA,
 Neurmberger EL, Grosset JH. Treatment of tuberculosis with rifamycin containing
 regimens in immune-deficient mice. Am J Respir Crit Care Med 2011; 183:1254 1261.
 10.1164/rccm.201012-1949OC
- 16. Chang KC, Leung CC, Yew WW, Chan SL, Tam CM. Dosing schedules of 6-month
 regimens and relapse for pulmonary tuberculosis. Am J Respir Crit Care Med 2006;
 174:1153 –1158. 10.1164/rccm.200605-637OC
- 402 17. Egelund EF, Peloquin CA. Pharmacokinetic variability and tuberculosis treatment
 403 outcomes, including acquired drug resistance. Clin Infect Dis 2012; 55:178–179.
 404 10.1093/cid/cis366
- 18. Devyani D, Alffenaar JW, Kose CU, Dheda K, Chapagain ML, Simbar N, Schon T, 405 Sturkenboom MGG, McIlleron H, Lee PS, Koeuth T, Mpagama SG, Banu S, Foongladda S, 406 **D-Cycloserine** Pholwat S. Houpt ER, Hevsell SK. Gumbo Τ. Ogarkov Ο, 407 Pharmacokinetics/Pharmacodynamics susceptibility and dosing implications in multidrug-408 resistant tuberculosis: A Faustian deal. Clin Infect Dis 2018; 67: S308-316. doi: 409 10.1093/cid/civ624 410
- 411 19. Chigutsa E, Meredith S, Wiesner L, Padayatchi N, Harding J, Moodley P, Mac Kenzie WR,
 412 Weiner M, McIlleron H, Kirkpatrick CMJ. Population pharmacokinetics of ofloxacin in South
 413 African patients with multi-drug resistant tuberculosis. Antimicrob Agents Chemother 2012;
 414 56: 3857-3863. doi: 10.1128/AAC.00048-12
- 20. Chirehwa MT, McIlleron H, Rustomjee R, Mthiyane T, Onyebujoh P, Smith P, Denti P. Pharmacokinetics of pyrazinamide and optimal dosing regimens for drug-sensitive and

- 417 resistant tuberculosis. Antimicrob Agents Chemother. 2017;61:1-11. doi: 418 10.1128/AAC.00490-17
- 21.A K Hemanth Kumar, T Kannan, V Chandrasekaran, V Sudha, A Vijayakumar, K Ramesh,
 J Lavanya, Soumya Swaminathan, Geetha Ramachandran. Pharmacokinetics of thrice
 weekly rifampicin, isoniazid and pyrazinamide in adult tuberculosis patients in India. Int J
 Tuberc Lung Dis 2016; 20:1236-1241. doi: 10.5588/ijtld.16.0048
- 22. McIlleron H, Wash P, Burger A, Norman J, Folb PI, Smith P. Determinants of rifampin,
 isoniazid, pyrazinamide and ethambutol pharmacokinetics in a cohort of tuberculosis
 patients. Antimicrob Agents Chemother 2006; 50: 1170 1177
- 23. Ray J, Gardiner I, Marriott D. Managing antituberculosis drug therapy by therapeutic drug
 monitoring of rifampicin and isoniazid. Intern Med J 2003; 33:229 234
- 24. Nijland HM, Ruslami JR, Stalenhoef JE, Nelwan EJ, Alisjahbana B, Nelwan RHH, van der
 Ven JAM, Danusantoso H, Aarnoutse RE, van Crevel R. Exposure of Rifampin is strongly
 reduced in tuberculosis patients with type 2 diabetes. Clin Infect Dis 2006; 43: 848 854
- 431 25. Hemanth Kumar AK, Chandrasekaran V, Kannan T, Lakshmi Murali, Lavanya J, Sudha V,
 432 Soumya Swaminathan, Geetha Ramachandran. Anti-tuberculosis drug concentrations in
 433 tuberculosis patients with and without diabetes mellitus. Eur J Clin Pharmacol 2017; 73: 65
 434 70. doi: 10.1007/s00228-016-2132-z
- 26. Babalik A, Ulus IH, Bakirci N, Kuyucu T, Arpag H, Dagyildizi L, Capaner E. Plasma
 Concentrations of Isoniazid and Rifampin are decreased in adult pulmonary tuberculosis
 patients with diabetes mellitus. Antimicrob Agents Chemother. 2013; 5740 5742. doi:
 10.1128/AAC.01345-13
- 27. Deshpande D, Pasipanodya JG, Mpagama SG, Srivastava S, Bendet P, Koeuth T, Lee PS,
 Heysell SK, Gumbo T. Ethionamide Pharmacokinetics/Pharmacodynamics- derived dose,
 the role of MICs in clinical outcome, and the resistance arrow of time in multidrug-resistant
 tuberculosis. Clin Infect Dis 2018; 67 :S317-326. doi: 10.1093/cid/ciy609
- 28. Forsman LD, Niward K, Hu Y, Zheng R, Zheng X, Ke R, Cai W, Hong C, Li Y, Gao Y,
 Werngren J, Paues J, Kuhlin J, Simonsson USH, Eliasson E, Alffenaar JW, Mansjo M,
 Hoffner S, Xu B, Schon T, Brushfeld J. Plasma concentrations of second-line antituberculosis drugs in relation to minimum inhibitory concentrations in multidrug-resistant
 tuberculosis patients in China: a study protocol of a prospective observational cohort study.
 BMJ Open 2018; 4;8:e023899. doi: 10.1136/bmjopen-2018-023899
- 449
- 450
- 451

	medRxiv preprint doi: https://doi.org/10.1101/2020.05.26.20111534; this version posted May 27, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
452	
453	
454	
455	
456	
457	
458	
459	
460	
461	

Table 1: Drug doses and weight bands followed in the PMDT guidelines

		INTENSIVE PHASE				
DRUGS	16 - 29 kg	30 - 45 kg	46 - 70 kg	ABC	OVE 70 kg	
LFX	250	750	1000		1000	
ETH	375	500	750		1000	
CS	250	500	750		1000	
EMB	400	800	1200		1600	
PZA	750	1250	1750		2000	
КМ	500	750	750		1000	
		NTINUATION PHAS	1			
DRUGS	16 - 29 kg	30 - 45 kg	46 - 70 kg	ABC)VE 70 kg	
LFX	250	750	1000		1000	
ETH	375	500	750		1000	
CS	250	500	750		1000	
EMB	400	800	1200	1200		
		MDR SHORTEF	REGIMEN			
		INTENSIVE PHASE				
DRUGS		16 - 29 kg	30 - 45 kg	46 - 70 kg	ABOVE 70 kg	
HIGH DOSE	MFX	400	600	800	800	
HIGH DOSE	INH	300	600	900	900	
PZA		750	1250	1750	2000	
ETH		375	500	750	1000	
CFZ		50	100	100	200	
EMB		400	800	1200	1600	

	All rights reserved. N	o reuse allowed withou	t permission.	
КМ	50	0 75	0 750	1000
	CONTINUATI	ION PHASE (5 MO	NTHS)	
DRUGS	16 - 2	.9 kg 30 - 4	5 kg 46 - 70 kg	ABOVE 70 kg
MFX	40			800
CFZ	50			200
PZA	75			2000
EMB	40			1600
FX - Levoflo	kacin; ETH - Ethionamide; CS - Cyclos	erine; EMB - Etham	outol; PZA - Pyrazinamic	de; KM - Kanamyci
	Table 2: Pa	tient Details (n =	· 350)	
	Parameter Age, years, Median (IQR Condor		n (%) 45 (34 - 55)	
	Gender	Female	62 (17.7%)	
	Gender	Female Male	62 (17.7%) 288 (82.3%)	
	BMI, kg/m ² , Median (IQ	Male		
		Male		
	BMI, kg/m², Median (IQ	Male R)	288 (82.3%)	
		Male R) <18.5 ≥ 18.5	288 (82.3%) 218 (62.3%) 132 (37.7%)	
	BMI, kg/m², Median (IQ	Male R) ≥ 18.5 No	288 (82.3%) 218 (62.3%) 132 (37.7%) 203 (58.0%)	
	BMI, kg/m ² , Median (IQ Diabetes	Male R) <18.5 ≥ 18.5	288 (82.3%) 218 (62.3%) 132 (37.7%)	
	BMI, kg/m², Median (IQ	Male R) <18.5 ≥18.5 No Yes	288 (82.3%) 218 (62.3%) 132 (37.7%) 203 (58.0%) 147 (42.0%)	
	BMI, kg/m ² , Median (IQ Diabetes	Male R) <18.5 ≥ 18.5 No Yes No	288 (82.3%) 218 (62.3%) 132 (37.7%) 203 (58.0%) 147 (42.0%) 249 (71.1%)	
	BMI, kg/m ² , Median (IQ Diabetes Smoking Status	Male R) <18.5 ≥18.5 No Yes	288 (82.3%) 218 (62.3%) 132 (37.7%) 203 (58.0%) 147 (42.0%)	
	BMI, kg/m ² , Median (IQ Diabetes	Male R) <18.5 ≥ 18.5 No Yes No	288 (82.3%) 218 (62.3%) 132 (37.7%) 203 (58.0%) 147 (42.0%) 249 (71.1%)	

Type of TB

Extra Pulmonary TB 10 (2.9%)

Yes

114 (32.6%)

Parameters	5	n (%)
	Pulmonary TB	340 (97.1%)
Past History of TB		
	No	31 (8.9%)
	Yes	319 (91.1%)
Category of ATT		
	Category I	49 (14.0%)
	Category II	246 (70.3%)
• • •	Others	55 (15.7%)
Smear Status		
	Negative	105 (30.0%)
	Positive	245 (70.0%)
Culture Status	Nesstine	110 (21 40/)
	Negative	110 (31.4%)
Biochemical Parameters	Positive	240 (68.6%)
	oglobin (g/dl)	11.8 (10.5 - 13.4)
	ucose (mg/dl)	127 (98.5 - 231.5)
	tinine (mg/dl)	0.9(0.7 - 1.0)
Alanine Pyruvate Trans		25 (20 - 29)
Dose mg/kg body weight	· · · /	23 (20 23)
Moxifloxacin	-	15.0 (13.0 - 16.2)
Levofloxacin		18.8 (17.4 - 20.8)
Ethionamide		13.5 (12.5 – 15.0)
Cycloserine		13.6 (12.5 – 15.0)
Isoniazid		15.4 (13.8 - 17.3)
Pyrazinamide		30.0 (27.8 – 33.0)
Ethambutol		21.6 (19.7 – 24.0)

PK Parameters	Levofloxacin n = 252	Ethionamide n = 259	Cycloserine n = 235	Pyrazinamide n = 300	Moxifloxacin n = 69	Isoniazid (300/600mg dose) n = 40	Isoniazid (900mg dose) n = 23
	11.6	2.5	37.5	48.9	5.6	10.5	11.8
Cmax, μg/ml	(9.3 - 14.4)	(2.0 - 2.5)	(28.3 - 47.9)	(38.7 - 60.3)	(3.9 - 8.1)	(7.8 - 15.9)	(7.2 - 19.5)
	2	2	2	2	2	2	2
Tmax, h	(1 - 4)	(2 - 2)	(2 - 4)	(2 - 4)	(2 - 4)	(1 - 2)	(1 - 2)
	88.6	15.2	344.3	453.9	43.1	58.3	74.6
AUC $_{0-12}$, µg/ml.h	(69.7 - 111.4)	(10.5 - 15.2)	(263.8 - 454.6)	(336.4 - 576.6)	(30.1 - 64.9)	(40.0 - 102.4)	(36.7 - 113.1)
	8.0	3.4	16.3	12.7	7.0	4.8	4.7
T _{1/2} , h	(6.2 - 11.2)	(2.2 - 3.4)	(11.6 - 24.1)	(9.6 - 16.8)	(5.7 - 8.8)	(3.6 - 6.3)	(3.5 - 6.6)
No (%) of Patients with Cmax							
Below therapeutic Range	34 (13.5%)	71 (27.4%)	16 (6.8%)	10 (3.3%)	7 (10.1%)	3 (7.5%)	6 (26.1%)
Within therapeutic Range	126 (50.0%)	171 (66.0%)	83 (35.3%)	211 (70.3%)	22 (31.9%)	3 (7.5%)	11 (47.8%)
Above therapeutic Range	92 (36.5%)	17 (6.6%)	136 (57.9%)	79 (26.3%)	40 (58.0%)	34 (85.0%)	6 (26.1%)

Table 3: Pharmacokinetic parameters of drugs(Values are given as Median & Inter quartile range)

483

484 Therapeutic Range: LFX: 8 – 13 μg/ml; ETH: 2 – 5 μg/ml; CS: 20 – 35 μg/ml; PZA: 20 – 60 μg/ml; MFX: 3 – 5 μg/ml; INH: 3 – 6 μg/ml; C_{max} = Peak

485 Concentration; T_{max} = Time at which peak concentration was attained; AUC = area under the time concentration curve; T1/2 = half-life

486

487

		Levofloxacin (µg/ml)	E	thionamide (μg/ml)		Cycloserine (µg/ml)		Pyrazinamide (µg/ml)		Moxifloxacin (μg/ml)		lsoniazid (μg/ml)
Parameters	n	Median (IQR)	n	Median (IQR)	n	Median (IQR)	n	Median (IQR)	n	Median (IQR)	n	Median (IQR)
Age, years												
<45	128	11.2 (9.1 - 13.7)	121	2.4 (1.9 - 3.4)	120	37.0(28.3 - 45.4)	140	50.6 (39.4 - 59.8)	26	5.1 (3.6 - 7.4)	25	9.9 (7.8 - 14.2)
≥45	124	12.0 (9.6 - 15.9)	138	2.7 (2.0 - 3.8)	115	38.5 (28.3 - 48.7)	160	47.9 (37.8 - 60.5)	43	5.7 (4.1 - 8.1)	38	13.1 (7.9 - 16.9)
P Value		0.041		0.151		0.222		0.791		0.396		0.232
Gender												
Female	38	11.6 (9.3 - 15.1)	37	2.5 (1.9 - 3.9)	34	33.6 (26.5 - 40.6)	57	52.1 (41.1 - 59.6)	20	5.2 (3.9 – 7.0)	18	11.5 (7.5 - 16.1)
Male	214	11.6 (9.4 - 14.3)	222	2.6 (2.0 - 3.6)	201	37.9 (29.2 - 48.1)	243	48.6 (38.2 - 60.5)	49	5.7 (3.9 - 8.1)	45	11.1 (7.9 - 15.7)
P Value		0.759		>0.99		0.071		0.802		0.832		0.796
BMI, kg/m ²												
<18.5	157	11.2 (8.7 - 13.7)	151	2.5 (1.8 - 3.5)	147	36.2 (27.5 - 46.1)	184	47.9 (38.3 - 60.9)	41	6.1 (4.1 - 8)	41	11.1 (7.8 - 15.7)
≥18.5	95	12.2 (10.9 - 15.1)	108	2.6 (2.1 - 3.9)	88	42.5 (31.6 - 48.4)	116	50.1 (39.5 – 60.0)	28	5.0 (3.5 - 8.2)	22	10.7 (8.0 - 19.5)
P Value		0.004		0.051		0.025		0.977		0.396		0.806
Smoking Status												
No	177	11.6 (9.4 - 13.8)	182	2.5 (2.0 - 3.6)	167	37.2 (27.5 - 48.6)	214	50.9 (38.2 - 60.2)	52	5.5 (3.9 - 7.8)	48	11 (7.6 - 16.3)
Yes	75	11.6 (8.7 - 15.6)	77	2.8 (2.0 - 3.9)	68	38.9 (30.8 - 47.5)	86	47.7 (39.5 - 61.3)	17	5.7 (4.3 - 8.2)	15	12.4 (7.9 - 14.6)
P Value		0.814		0.611		0.406		0.960		0.723		0.987
Alcoholism												
No	166	11.4 (9.4 - 13.8)	171	2.5 (1.9 - 3.6)	153	36.2 (27.3 - 46.1)	200	50.4 (37.8 - 60.1)	50	5.6 (3.9 - 8.2)	46	10.9 (7.2 - 16.6)
Yes	86	11.8 (8.9 - 15.6)	88	2.9 (2.0 - 3.9)	82	39.7 (31.2 - 48.3)	100	48.0 (39.4 - 62.2)	19	5.6 (3.8 – 8.0)	17	12.4 (9.1 - 14.3)
P Value		0.419		0.258		0.055		0.879		0.523		0.733
Diabetes												
No	141	11.1 (9.0 - 13.7)	147	2.5 (2.0 - 3.6)	134	35.5 (27.4 - 45.1)	172	50.7 (39.3 - 60.4)	43	5.6 (4.0 – 8.0)	43	12.4 (7.8 - 16.1)
Yes	111	12.0 (10.0 - 15.1)	112	2.6 (1.9 - 3.9)	101	42.4 (31.2 - 49.4)	128	48.0 (37.8 - 60.3)	26	5.6 (3.9 - 8.2)	20	9.6 (6.4 - 17.3)
P Value		0.014		0.891		0.004		0.683		0.911		0.516
Culture Status												
Negative	59	11.6 (9.1 - 14.6)	84	2.9 (2.0 - 3.8)	52	37.1 (27.2 – 46.0)	96	50.1 (40.0 - 58.9)	39	5.4 (3.9 - 8.2)	35	13.6 (8.5 - 16.1)
Positive	193	11.5 (9.4 - 14.3)	175	2.5 (1.9 - 3.6)	183	37.6 (29.2 - 48.3)	204	48.7 (37.4 - 60.5)	30	5.7 (4 .0- 8.0)	28	9.5 (6.6 - 15.8)
P Value		0.857		0.040		0.525		0.854		0.785		0.125

Table 4: C_{max} of drugs among different patient groups

Table 5: AUC₀₋₁₂ of drugs among different patient groups

		Levofloxacin (µg/ml)		Ethionamide (μg/ml)		Cycloserine (µg/ml)		Pyrazinamide (μg/ml)		Moxifloxacin (μg/ml)		lsoniazid (μg/ml)
Parameters	n	Median (IQR)	n	Median (IQR)	n	Median (IQR)	n	Median (IQR)	n	Median (IQR)	n	Median (IQR)
Age, years												
<45	128	82.0 (67.0 - 105.2)	121	13.6 (10.0 - 20.4)	120	329.6 (260.6 - 436.1)	140	458.0 (336.4 - 560.3)	26	38.2 (27.1 - 60.3)	25	58.0 (40.6 - 83.8)
≥45	124	94.7 (73.6 - 119.6)	138	15.9 (11.3 - 21.8)	115	353.3 (266.6 - 466.2)	160	448.1 (335.4 – 605.0)	43	44.7 (32.1 - 69.9)	38	75.7 (39.7 - 112.4)
P Value		0.004		0.076		0.117		0.637		0.373		0.232
Gender												
Female	38	82.1 (61.5 - 103.8)	37	13.4 (10.0 - 21.1)	34	307.7 (227.1 - 392.3)	57	423.2 (313.1 - 552.2)	20	36.7 (30.4 – 53.0)	18	66.4 (43.4 - 102.3)
Male	214	89.9 (70.3 – 113.0)	222	15.4 (11.3 - 20.8)	201	354.8 (267.0 - 460.1)	243	454.7 (339.1 - 594.2)	49	47.9 (30.1 - 69.9)	45	65.2 (39.7 - 102.4)
P Value		0.134		0.716		0.004		0.269		0.308		0.704
BMI, kg/m ²												
<18.5	157	85.2 (66.0 - 108.9)	151	13.7 (9.9 - 20.3)	147	322.7 (260.2 - 447.7)	184	443.7 (335.2 - 591.3)	41	49.3 (32.4 - 64.2)	41	63.9 (39.7 - 97.1)
≥18.5	95	94.3 (75.8 - 112.9)	108	15.7 (11.7 - 21.9)	88	401.6 (296.6 - 457.4)	116	468.4 (336.9 - 568.9)	28	36.7 (29.1 - 67.4)	22	75.4 (40.6 - 113.1)
P Value		0.048		0.060		0.015		0.629		0.406		0.395
Smoking Status												
No	177	87.8 (69.8 - 112.9)	182	15.2 (10.4 - 21.1)	167	333.1 (258.2 - 454.6)	214	451.5 (333.9 - 573.7)	52	42.0 (29.8 - 62.3)	48	64.8 (40.0 - 104.1)
Yes	75	90.7 (68.9 - 111.4)	77	15.4 (11.3 - 20.4)	68	369.5 (287.7 - 453.5)	86	454.9 (341.8 - 594.2)	17	44.7 (32.1 - 71.3)	15	65.2 (39.7 - 97.1)
P Value		0.579		0.905		0.218		0.671		0.568		0.910
Alcoholism												
No	166	87.5 (67.4 - 111.3)	171	14.4 (10.0 - 20.8)	153	323.4 (251.3 - 446.8)	200	457.5 (332.2 - 574.2)	50	42.0 (30.1 - 64.9)	46	64.8 (36.7 - 103.8)
Yes	86	90.8 (70.6 - 117.6)	88	17.6 (11.5 - 21.4)	82	383.9 (302.6 - 466.2)	100	451.0 (347.0 – 580.0)	19	43.5 (29.4 - 66.8)	17	65.2 (40.6 - 85.2)
P Value		0.321		0.226		0.017		0.754		0.747		0.865
Diabetes												
No	141	84.3 (65.6 - 108.9)	147	14.1 (10.8 - 21.4)	134	323.9 (251.2 - 430.4)	172	460.6 (339.9 - 583.4)	43	43.1 (31.6 - 64.2)	43	73.3 (39.7 - 102.4)
Yes	111	93.8 (75.8 - 112.9)	112	15.5 (10.4 - 20.4)	101	388.7 (300.5 - 466.2)	128	449.5 (333.6 - 571.6)	26	42.3 (29.5 - 69.8)	20	56.2 (38.7 - 107.7)
P Value		0.183		0.989		0.004		0.635		0.862		0.690
Culture Status												
Negative	59	87.1 (67.0 - 114.5)	84	16.8 (11.4 – 23.0)	52	337.6 (238.6 - 437.1)	96	453.9 (336.9 - 560.6)	39	41.1 (29.4 - 64.9)	35	78.2 (48.3 - 104.3)
Positive	193	89.4 (70.3 – 109.0)	175	14.4 (10.0 - 20.2)	183	348.8 (264.1 - 459.1)	204	454.1 (335.6 - 591.9)	30	43.3 (32.4 - 66.8)	28	49.9 (36.8 – 82.0)
P Value		0.933		0.034		0.250		0.933		0.654		0.638

Drug		Peak Con	centration	Exposure					
Drug	OR (95% CI)	P Value	aOR (95% CI)	P Value	OR (95% CI)	P Value	aOR (95% CI)	P Value	
	0.993	0.872	1.001	>0.950	0.999	0.802	0.999	0.875	
LFX	(0.915 - 1.078)		(0.919 - 1.090)		(0.990 - 1.008)		(0.990 - 1.009)		
CTU	1.321	0.118	1.262	0.198	1.068	0.034	1.065	0.047	
ETH	(0.931 - 1.874)		(0.885 - 1.799)		(1.005 - 1.136)		(1.001 - 1.134)		
00	1.014	0.332	1.010	0.503	1.002	0.273	1.001	0.498	
CS	(0.986 - 1.043)		(0.981 - 1.041)		(0.999 - 1.004)		(0.998 - 1.004)		
D7A	0.992	0.429	0.993	0.523	0.999	0.509	0.999	0.523	
PZA	(0.972 - 1.012)		(0.974 - 1.014)		(0.997 - 1.001)		(0.997 - 1.001)		
16111	0.974	0.745	0.960	0.814	1.000	>0.950	1.043	0.912	
INH	(0.828 - 1.144)		(0.799 - 1.240)		(0.974 - 1.026)		(0.980 - 1.040)		
	0.821	0.318	0.880	0.451	0.976	0.333	0.990	0.512	
MFX	(0.557 - 1.210)		(0.520 - 1.490)		(0.930 - 1.025)		(0.910 - 1.240)		

Table 6: Impact of drug levels on status at end of intensive phase

Odds ratio was calculated after adjusting for the factors such as age, gender, body weight, smoking status, alcoholism and diabetes mellitus


495

496 LFX - Levofloxacin; ETH - Ethionamide; CS - Cycloserine; PZA - Pyrazinamide; INH - Isoniazid; MFX - Moxifloxacin

494

Figure 1: Boxplot (Median & IQR) comparing C_{max} (A) and AUC₀₋₁₂ (B) of drugs between responders and non-responders





B

